If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
926.00    -8.00 (-0.86%)
Bid:
922.00
Ask:
930.00
Spread: 8.00 (0.868%)
Market Cap: £253.45m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Life Sciences Acquisition

8 Aug 2018 07:00

RNS Number : 1631X
Gooch & Housego PLC
08 August 2018
Β 

For immediate release

8 August 2018

Β 

Β 

Β 

Β 

Gooch & Housego PLC

("G&H" or the "Company")

Β 

Life Sciences Acquisition

Β 

Β Further enabling G&H's move into system based products

Β 

Β 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of optical components & systems, announces that it has acquired the entire issued share capital of VITL Ltd ('ITL" or "Integrated Technologies Limited") for a total consideration of up to Β£22.0 million. This acquisition expands the Company's presence in the life sciences sector and further enables G&H's move into system based products.

Β 

ITL

Β 

Founded in 1977, ITL is a UK based specialist in the design, development and manufacture of high-quality medical and in vitro diagnostic (IVD) devices.

Β 

ITL is a market leading supplier with an established group of long standing multi national customers. It provides full product development, design, manufacturing and after sale service for the commercialisation of medical diagnostic, analytical, precision electro-mechanical and laboratory instruments. ITL is headquartered in Ashford, Kent, with manufacturing sites in Ashford and Shanghai, China, plus a US client servicing capability based in Virginia, USA.

Β 

This acquisition enables G&H to take a significant step towards meeting its strategic objectives, including doubling the revenue of its life science business and accelerating the Company's move up the value chain, with all of ITL's sales coming from system based products. ITL's core group of electronic, software and mechanical engineers, provides an enhanced platform on which G&H can expand its systems capabilities.

Β 

Over time there are a number of potential benefits that will accrue from ITL becoming part of G&H. These include leveraging G&H's footprint in the US, China and Far East and combining the Company's photonic expertise with ITL's high level systems capability in order to provide a more attractive product offering to G&H's medical diagnostic customer base.

Β 

Terms of acquisition

Β 

The total consideration payable by G&H is up to Β£22.0 million. This comprises an initial cash consideration of Β£14.0 million, funded from existing resources, together with Β£1.4 million of new G&H shares. There is also a deferred contingent cash consideration of up to Β£8.0 million, based upon the performance of the business over the next two years. The Company has made an application to the London Stock Exchange for the 92,684 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will become effective on or around 14 August 2018.

Β 

The historical annual revenue of ITL was c.Β£10 million, adjusted operating profit was c.Β£1.5 million and the acquisition is expected to be earnings enhancing in the first full financial year of G&H's ownership. Historical gross assets were cΒ£7 million.

Β 

Β 

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"This acquisition provides a key step towards achieving our strategic aims of establishing 'critical mass' in our life sciences business and moving up the value chain, through a more systems based product portfolio.

"It means we are able to continue to diversify our business, allow G&H access to new high growth markets, as well as reducing, still further, dependency on the historically cyclical micro-electronic sector.

"ITL is a high quality business, with a long standing customer base, excellent engineering capabilities and a strong financial track record.Β 

"We are very much looking forward to working with the management, staff and customers of ITL."

Β 

Β 

For further information contact: -

Β 

Β 

Β 

Mark Webster / Andrew Boteler

Gooch & Housego PLC

01460 256440

Mark Court/ Sophie Wills

Buchanan

020 7466 5000

Patrick Robb / David Anderson

Investec Bank plc

020 7597 5970

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Notes to editors

Β 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

Β 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
ACQEVLBBVVFLBBQ
Date   Source Headline
23rd Jul 20127:00 amRNSProgress Update
12th Jun 20127:00 amRNSInterim Results
22nd May 20127:00 amRNSNotification of Interim Results
5th Apr 20127:00 amRNSHalf-Year Trading Update
14th Mar 20128:59 amRNSAIM Rule 20 - Annual Report
23rd Feb 201212:45 pmRNSAppointment of non-executive director
23rd Feb 20127:00 amRNSResults of Annual General Meeting
21st Feb 20127:00 amRNSTrading Update
29th Nov 20117:00 amRNSPreliminary Results
4th Nov 20114:35 pmRNSPrice Monitoring Extension
4th Oct 20117:00 amRNSFull-Year Trading Update
29th Sep 201111:52 amRNSBoard Change
8th Jun 20117:00 amRNSInterim Results
12th May 201112:24 pmRNSNotice of Results
1st Apr 20117:00 amRNSAcquisition and Trading Update
23rd Feb 20117:00 amRNSProgress Update for Today's Annual General Meeting
28th Jan 20118:10 amRNSDirector/PDMR Shareholding
25th Jan 20118:30 amRNSAcquisition of EM4
24th Jan 201112:07 pmRNSAdditional Listing
19th Jan 201111:45 amRNSUS Regulatory Approval
13th Jan 20114:55 pmRNSNotification of Interests
13th Jan 20114:55 pmRNSDirector Shareholdings
13th Jan 20114:53 pmRNSAdditional Listing
5th Jan 20111:42 pmRNSResult of EGM
16th Dec 20102:37 pmRNSProposed Acquisition, Placing and General Meeting
2nd Dec 20108:52 amRNSDividend
30th Nov 20107:00 amRNSPreliminary Results
15th Nov 20107:00 amRNSNotice of Results
5th Oct 20107:00 amRNSFull-Year Trading Update
17th Sep 20102:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSTrading Update
8th Jun 20107:00 amRNSInterim Results
18th May 20107:00 amRNSNotice of Results
8th Apr 20107:00 amRNSHalf-Year Trading Update
26th Mar 20103:33 pmRNSHolding(s) in Company
12th Mar 20108:56 amRNSDirector/PDMR Shareholding
25th Feb 201011:00 amRNSResult of AGM
24th Feb 20107:00 amRNSProgress Update for Today's Annual General Meeting
26th Jan 20108:24 amRNSDirector/PDMR Shareholding
18th Jan 20103:48 pmRNSAward of Share Options
7th Jan 20103:09 pmRNSAward of share-based incentives
1st Dec 20097:00 amRNSPreliminary Results
12th Nov 20098:56 amRNSNotice of Results
6th Oct 20097:00 amRNSFull-Year Trading Update
23rd Jul 20097:00 amRNSAppointment of new executive director
9th Jun 20097:00 amRNSInterim Results
13th May 20098:57 amRNSNotice of Results
2nd Apr 20097:00 amRNSResult of AGM
31st Mar 20097:00 amRNSHalf-Year Trading Update
23rd Mar 20097:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.